MiMedx Group, Inc. (MDXG)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$3.28+2.50%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · MDXG
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | ||||||||||||||||
| Revenues | 303.7 | 418.6 | 348.9 | 321.5 | 267.8 | 258.6 | 248.2 | 299.3 | 359.1 | 321.1 | 221.7 | 187.3 | 118.2 | 59.2 | 27.1 | 7.8 |
| Total Revenues | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 7.8 |
| Cost of Revenues | 69.0 | 73.0 | 60.1 | 54.6 | 48.3 | 43.3 | 39.3 | 43.1 | 36.4 | 35.2 | 30.9 | — | — | — | — | — |
| Gross Profit | 234.7 | 345.6 | 288.8 | 266.8 | 219.5 | 215.3 | 208.9 | 256.2 | 322.7 | 285.9 | 190.8 | 167.1 | 105.6 | 49.9 | — | — |
| Operating Expenses & Income | ||||||||||||||||
| Selling, General & Admin | 244.4 | 266.2 | 225.1 | 211.1 | 208.8 | 198.4 | 181.0 | 198.2 | 258.5 | 220.1 | 173.4 | 133.4 | 90.5 | 46.2 | 19.6 | 9.8 |
| R&D Expenses | 14.5 | 15.1 | 12.3 | 12.7 | 22.8 | 17.3 | 11.7 | 11.1 | 15.8 | 17.9 | 14.3 | 8.4 | 7.1 | 4.8 | 2.9 | 3.0 |
| Operating Income | (25.1) | 63.9 | 58.9 | 37.1 | (25.0) | (5.0) | (45.4) | (21.2) | (3.9) | 46.2 | 0.9 | 24.4 | 7.1 | (2.6) | (5.4) | (9.8) |
| Earnings from Continuing Operations | ||||||||||||||||
| Interest Expense | — | 1.8 | 3.9 | — | — | — | — | — | — | — | 0.3 | 0.1 | 0.0 | 0.0 | 0.6 | 0.1 |
| Interest & Investment Income | — | 4.7 | 2.9 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Asset Writedown | — | — | — | — | — | — | — | 0.4 | — | 0.0 | — | — | — | — | — | — |
| EBT, Incl. Unusual Items | (22.4) | 66.3 | 57.3 | 30.6 | (30.0) | (10.0) | (61.5) | (25.6) | (3.4) | 45.1 | 0.5 | 24.3 | 7.1 | (4.0) | (7.7) | (10.2) |
| Income Tax Expense | (3.2) | 17.7 | 15.3 | (36.8) | 0.2 | 0.2 | (12.3) | (0.0) | 26.6 | (19.6) | 0.2 | (5.2) | 0.8 | 0.1 | 0.0 | 0.0 |
| Net Income | ||||||||||||||||
| Net Income | (19.2) | 48.6 | 42.4 | 58.2 | (30.2) | (10.3) | (49.3) | (25.6) | (30.0) | 64.7 | 0.4 | 29.4 | 6.2 | (4.1) | (7.7) | (10.2) |
| Per Share | ||||||||||||||||
| Basic EPS | (0.13) | 0.33 | 0.29 | 0.40 | (0.33) | (0.15) | (0.77) | (0.24) | (0.28) | 0.61 | 0.00 | 0.28 | 0.06 | — | — | — |
| Diluted EPS | (0.13) | 0.32 | 0.28 | 0.37 | (0.33) | (0.15) | (0.77) | (0.24) | (0.28) | 0.56 | 0.00 | 0.26 | 0.05 | — | — | — |
| Revenue per Share | 2.08 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Basic Weighted Avg Shares | 145.9 | 147.8 | 147.0 | 116.5 | 112.9 | 110.4 | 108.3 | 106.9 | 105.6 | 106.1 | 105.9 | 105.9 | 105.8 | 96.3 | 81.6 | — |
| Diluted Weighted Avg Shares | 145.9 | 149.7 | 149.0 | 146.0 | 112.9 | 110.4 | 108.3 | 106.9 | 105.6 | 116.1 | 112.6 | 113.6 | 113.3 | 96.3 | 81.6 | — |
| Supplemental | ||||||||||||||||
| EBITDA | — | 78.8 | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| EBIT | (25.1) | 63.9 | 58.9 | 37.1 | (25.0) | (5.0) | (45.4) | (21.2) | (3.9) | 46.2 | 0.9 | 24.4 | 7.1 | (2.6) | (5.4) | (9.8) |
| Effective Tax Rate | 14.2% | — | — | — | — | — | — | — | — | -43.6% | 28.4% | -21.3% | 11.8% | -2.5% | 0.0% | 0.0% |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.